Watching NuCana; Traders Circulate Oppenheimer Note Saying "First Look From NCNA's Randomized Phase 2 Trial In Metastatic Colorectal An Efficacy Advantage On Progression-free Survival Would Be A Home Run"; Gives Buy Rating With 12-18 Month $150 PT
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer has issued a buy rating for NuCana (NCNA) with a 12-18 month price target of $150. The note highlights the potential efficacy advantage in progression-free survival from NuCana's Phase 2 trial in metastatic colorectal cancer as a significant positive indicator.
August 19, 2024 | 4:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer's buy rating and $150 price target for NuCana is based on promising results from a Phase 2 trial in metastatic colorectal cancer, indicating a potential efficacy advantage.
The buy rating and high price target from Oppenheimer are likely to positively influence NuCana's stock price in the short term. The mention of a potential efficacy advantage in a Phase 2 trial is a strong indicator of future success, which is critical for biotech companies.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100